Medical Product Communications Consistent With FDA-Required Labeling Draft Guidance: Navigating the Gray Zone

Posted 25 October 2017 By Nikki Foeller

placeholder+image This article discusses the changing landscape for promotional review regarding the shift in evidentiary standards introduced in the 2017 Consistent with the Label Draft Guidance. It also highlights industry perspectives for consideration to companies looking to apply the principles outlined in the Draft Guidance or in preview to what could be addressed in a future revision.

Share this article:

Categories: Drugs, Features, US, FDA, Communication

Tags: Labeling, Medical Product Communications

Regulatory Exchange: Latest Updates From the Community